Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Growth Factors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT06444503
What this trial is testing

Clinico-biological Collection of Bone, Calcium and Growth Plate Pathologies

Who this might be right for
Bone Disorder
University Hospital, Toulouse 350
Not applicableStudy completedNCT02475720
What this trial is testing

Survey on the Treatment Reality of Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer(NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
AstraZeneca 2,000
Early research (Phase 1)Ended earlyNCT02365662
What this trial is testing

A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor

Who this might be right for
Head and Neck Squamous Cell CarcinomaNon-small Cell Lung CancerTriple Negative Breast Cancer+2 more
AbbVie 46
Early research (Phase 1)Study completedNCT00047346
What this trial is testing

Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction

Who this might be right for
Adult Primary Hepatocellular CarcinomaAdvanced Adult Primary Liver CancerLocalized Unresectable Adult Primary Liver Cancer+1 more
National Cancer Institute (NCI) 24
Testing effectiveness (Phase 2)Looking for participantsNCT05735080
What this trial is testing

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Who this might be right for
Breast CancerBreast Cancer MetastaticHormone Receptor Positive Tumor+6 more
Incyclix Bio 150
Not applicableStudy completedNCT02195388
What this trial is testing

Focus On Stiffness Reduction, Endothelial Function and Autonomic Nervous System

Who this might be right for
Arterial StiffnessEndothelial FunctionAutonomic Nervous System+2 more
Medical University of Lodz 120
Early research (Phase 1)UnknownNCT04375618
What this trial is testing

RhEGF Incorporated in An Absorbable Collagen Membrane for The Management Of Gingival Recession Defects

Who this might be right for
Periodontitis
SVS Institute of Dental Sciences 30
Not applicableUnknownNCT05100550
What this trial is testing

Family-based Health Education Program and Zinc Supplementation for Stunted Mother

Who this might be right for
StuntingMaternal-Fetal Relations
Hasanuddin University 126
Large-scale testing (Phase 3)UnknownNCT04500704
What this trial is testing

Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 166
Early research (Phase 1)Study completedNCT01733004
What this trial is testing

MM-141 in Patients With Advanced Solid Tumors

Who this might be right for
Hepatocellular Carcinoma
Merrimack Pharmaceuticals 42
Not applicableStudy completedNCT06985121
What this trial is testing

Scalp Care Efficacy Evaluation for Premium Scalp Revitalizing Essence

Who this might be right for
Scalp HealthHair ConditionHair Loss+2 more
Hungkuang University 60
Not applicableUnknownNCT04132635
What this trial is testing

A Trial to Evaluate the Combination Efficacy of Artificial Dermis and Growth Factor in Chronic Wounds Ulcer

Who this might be right for
Chronic Wound
Second Affiliated Hospital, Zhejiang University, School of Medicine 64
Large-scale testing (Phase 3)Looking for participantsNCT06712316
What this trial is testing

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
BioNTech SE 1,580
Testing effectiveness (Phase 2)Looking for participantsNCT06511648
What this trial is testing

Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations

Who this might be right for
Muscle-invasive Bladder Cancer
Spanish Oncology Genito-Urinary Group 90
Not applicableStudy completedNCT00709878
What this trial is testing

Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors

Who this might be right for
Skin Rash
Northwestern University 32
Testing effectiveness (Phase 2)Study completedNCT03280563
What this trial is testing

Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Who this might be right for
Breast Neoplasms
Hoffmann-La Roche 144
Testing effectiveness (Phase 2)Ended earlyNCT00784693
What this trial is testing

A Clinical Study To Investigate The Effectiveness And Safety Of Tanezumab In Treating Pain Associated With Endometriosis

Who this might be right for
Endometriosis
Pfizer 48
Testing effectiveness (Phase 2)UnknownNCT00797706
What this trial is testing

Phase I/II Dose Ranging CHRONSEAL® Study in Venous Leg Ulcers

Who this might be right for
Chronic Venous Leg Ulcers
Kringle Pharma Europe AB 75
Early research (Phase 1)WithdrawnNCT01152658
What this trial is testing

Partial Tear of Supraspinatus (SSP) and Treatment With Plasma Rich in Growth Factors (PRGF)

Who this might be right for
Partial Supraspinatus Tear
Meir Medical Center
Testing effectiveness (Phase 2)Ended earlyNCT06408168
What this trial is testing

Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)

Who this might be right for
Hormone Receptor-positive Human Epidermal Growth Factor 2-negativeMetastatic Invasive LObular Carcinoma
M.D. Anderson Cancer Center 6
Next Page